CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Affini-T Therapeutics
Main (gene editing) focus: Next-generation cell therapies
Company stage: Pre-clinical
Diseases: Solid tumours
Genome editing tool: CRISPR
Funding stage: Private
Location: Boston, MA, USA
Website: https://affinittx.com/
Pipeline: https://affinittx.com/pipeline/
Partners: Metagenomi
Affini-T Therapeutics is focused on developing pioneering engineered T cell receptor (TCR) T cell therapies. The company's involvement in the gene-editing space comes through its partnership with Metagenomi, although lead programmes have yet to be announced as well as the specifics regarding the gene-editing system in use.
